• Recurrent or refractory neuroblastoma or solid tumor.

• Physical state score ≥ 50.

• Expected survival ≥ 3 months.

• There are target lesions (neuroblastoma) or measurable lesions (other solid tumors).

• Have adequate organ function.

• Fresh or archived tumor tissue samples should be provided prior to treatment. If none of these specimens are available, inclusion may be made after consultation with the sponsor.

• Fertile women (≥14 years of age or having menarche) must have a negative serum pregnancy test at the time of the screening visit and must not be breastfeeding or planning to become pregnant during the study period.

• A potentially fertile male subject (who has spermatoses) or female subject (ibid.) must agree to use effective contraception during the trial period and for 3 months after the trial ends (or is prematurely discontinued).

• Informed consent must be obtained before carrying out any study procedure specified in the test. For child subjects, the consent of the subject and one of the parent/legal guardian must be obtained.

⁃ The ability to swallow research drugs.